Evolus (EOLS) Interest & Investment Income (2019 - 2026)
Evolus' (EOLS) quarterly Interest & Investment Income came in at $285000.0 in Q1 2026, down 59.86% YoY from $710000.0 in Q1 2025, and up 8.37% on a QoQ basis from $263000.0 in Q4 2025.
Evolus (EOLS) Interest & Investment Income (2019 - 2026) Analysis & Trends
Evolus (EOLS) has 8 years of Interest & Investment Income data on file, last reported at $285000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 59.86% year-over-year to $285000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 56.42% YoY) and the FY2025 annual result came in at $1.9 million, down 40.82% from the prior year.
- Interest & Investment Income advanced to $285000.0 in Q1 2026, from $263000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $1.0 million in Q2 2024 to a low of -$203000.0 in Q3 2022.
- A 5-year average of $333764.7 and a median of $291000.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 3000.0% — and 2023, when it sank 1400.0%.
- Tracing EOLS's Interest & Investment Income over 5 years: stood at $31000.0 in 2022, then jumped by 838.71% to $291000.0 in 2023, then jumped by 171.13% to $789000.0 in 2024, then slumped by 66.67% to $263000.0 in 2025, then advanced by 8.37% to $285000.0 in 2026.
- The last three Interest & Investment Income figures came in at $285000.0 (Q1 2026), $263000.0 (Q4 2025), and $479000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | 296,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 296,000.00 |
| Mar 31, 2026 | 285,000.00 |
| Dec 31, 2025 | 263,000.00 |
| Sep 30, 2025 | 479,000.00 |
| Jun 30, 2025 | 479,000.00 |
| Mar 31, 2025 | 710,000.00 |
| Dec 31, 2024 | 789,000.00 |
| Sep 30, 2024 | 928,000.00 |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 517,000.00 |
| Dec 31, 2023 | 291,000.00 |
| Sep 30, 2023 | 306,000.00 |
| Jun 30, 2023 | -52,000.00 |
| Mar 31, 2023 | -79,000.00 |
| Dec 31, 2022 | 31,000.00 |
| Sep 30, 2022 | -203,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Mar 31, 2022 | -103,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Dec 31, 2020 | -3,000.00 |